Gene editing, particularly using the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system, is now being extensively used as a research and functional screening tool in drug discovery. Cambridge Healthtech Institute’s second annual conference on Translational Gene Editing will bring together experts from all aspects of preclinical research, from early target discovery to drug delivery, to talk about the progress being made in gene editing and how it’s being applied. Learn about ways in which CRISPR/Cas9 is being used to identify targets, create relevant cell lines and in vivo disease models, set up functional screens, and for targeted drug delivery. What can you do to overcome some of the inherent challenges with design, delivery and off-target effects associated with CRISPR/Cas9? Hear from experts in pharma/biotech, academic and government labs who will share their experiences leveraging the utility of gene editing for diverse applications, particularly in oncology and immunotherapy.